Phase II, Open Label, Randomized, Two Treatment Groups, Study Assessing Pharmacokinetics After Administration of the Once Weekly and Once Monthly, Long Acting Subcutaneous Injection of CAM2038 in Opioid Dependent Subjects With Chronic Pain
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Jul 2017
At a glance
- Drugs Buprenorphine (Primary)
- Indications Opioid abuse; Pain
- Focus Pharmacokinetics
- Sponsors Braeburn Pharmaceuticals
- 12 Jul 2017 Topline results published in the Braeburn Pharmaceutical media Release.
- 07 Oct 2016 Planned End Date changed from 1 Sep 2016 to 1 Mar 2017.
- 07 Oct 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Mar 2017.